预约演示
更新于：2025-08-23
Guanfacine hydrochloride
盐酸胍法辛
更新于：2025-08-23
概要
基本信息
简介胍法辛（商品名为Tenex、Intuniv、Estulic）是一种作用于中枢的降压剂和α2肾上腺素受体激动剂。其作用机制是刺激脑内的α2肾上腺素受体，导致交感神经系统活动降低，从而降低血压。此外，胍法辛已被发现对调节注意力和行为的前额叶皮层产生影响，因此对治疗注意力缺陷多动障碍（ADHD）有用。胍法辛最初于1986年被FDA批准用于治疗高血压，授权公司是Promius Pharma LLC。随后在2009年，Takeda制药公司获得了美国批准，用于治疗儿童和青少年的ADHD。目前，它在世界多个国家获得了批准。 |
药物类型 小分子化药 |
别名 Connexyn、guanfacine、Guanfacine hydrochloride (JAN/USP) + [10] |
作用方式 激动剂 |
作用机制 adrenergic receptor激动剂(肾上腺素能受体家族激动剂) |
治疗领域 |
在研适应症 |
最高研发阶段批准上市 |
首次获批日期 美国 (1986-10-27), |
最高研发阶段(中国)临床3期 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C9H10Cl3N3O |
InChIKeyDGFYECXYGUIODH-UHFFFAOYSA-N |
CAS号29110-48-3 |
关联
87
项与 盐酸胍法辛 相关的临床试验NCT06408246
ACE-D: Accelerating Cognition-guided Signatures to Enhance Translation in Depression: Clinical Trial
NCT06629259
Guanfacine for Alcohol Use Disorder (AUD): a Telehealth Approach
NCT06642181
Combined Guanfacine and Mindfulness Meditation as an Adjunct to Buprenorphine Maintenance in Opioid Use Disorder
100 项与 盐酸胍法辛 相关的临床结果
登录后查看更多信息
100 项与 盐酸胍法辛 相关的转化医学
登录后查看更多信息
100 项与 盐酸胍法辛 相关的专利（医药）
登录后查看更多信息
1,413
项与 盐酸胍法辛 相关的文献（医药）2025-08-31Clinical Psychopharmacology and Neuroscience
Efficacy of Guanfacine for Self-injurious and Aggressive Behaviors through the Reduction of Impulsivity in Borderline Personality Disorder: Two Case Reports and a Literature Review
Article
作者: Ueno, Shu-ichi ; Ochi, Shinichiro ; Hashida, Hidetoshi ; Iga, Jun-ichi ; Mori, Hiroaki
Borderline personality disorder (BPD) is a complex psychiatric disorder characterized by emotional instability, impulsivity, and self-destructive behavior. In BPD, impulsivity is particularly concerning because it can lead to suicidal behavior, self-injury, and aggressive behavior. Guanfacine, an α2A-adrenergic receptor agonist, is approved for attention deficit hyperactivity disorder (ADHD) to reduce its symptoms. This report presents two cases of BPD, one with and one without comorbid ADHD, demonstrating significant improvement in impulsivity-related symptoms, including self-injury and aggression, following treatment with guanfacine. Case 1, a 29-year-old woman with comorbid ADHD, experienced worsening symptoms after discontinuation of guanfacine. Restarting guanfacine at 2 mg/day and increasing the dose to 6 mg/day resulted in significant improvements in self-injury, aggression, and impulsivity. Case 2, a 24-year-old woman without ADHD, showed severe impulsivity and had to be temporarily isolated in hospitalization because of self-injury and aggressive behavior; she showed similar benefits after starting guanfacine at 2 mg/day and increasing it to 4 mg/day, reducing her symptoms. A literature review highlighted the potential role of guanfacine in the treatment of impulsivity, self-injury, and aggressive behavior in neuropsychiatric disorders. Guanfacine is thought to improve prefrontal cortex (PFC) dysfunction. Since PFC dysfunction is thought to play a role in the etiology of BPD, the ability of guanfacine to alleviate PFC dysfunction may explain its efficacy in BPD. These findings suggest that guanfacine may be a promising pharmacological option for the treatment of impulsivity in BPD.
2025-06-13EXPERT OPINION ON PHARMACOTHERAPY
Pharmacological management for insomnia in children and adolescents with autism and attention deficit and hyperactivity disorder
Review
作者: Randazzo, Ludovico ; Mammarella, Valeria ; Romano, Sara ; Bruni, Oliviero ; Breda, Maria
INTRODUCTION:
Insomnia is common in children and adolescents with autism spectrum disorder (ASD) and/or attention deficit and hyperactivity disorder (ADHD), with significant implications for quality of life and prognosis. Although non-pharmacological interventions represent the first-line approach, they are not always effective. Therefore, it is important to determine when a pharmacological treatment can be indicated and which compound to prefer based on evidence of efficacy and safety.
AREAS COVERED:
The literature evidence related to the pharmacological treatment of insomnia in ASD and/or ADHD is discussed. We present data on drugs and supplements used and considerations about the choice of starting a pharmacological therapy, suggesting clinical advice that may guide clinicians.
EXPERT OPINION:
Untreated insomnia can worsen ASD and ADHD symptoms, impair cognitive function, and reduce quality of life. Targeted interventions are essential. Behavioral strategies, with or without melatonin, are recommended after evaluating comorbidities and medications. Off-label treatments for children with ASD include antihistamines, alpha-adrenergics, trazodone, antidepressants, antipsychotics, anticonvulsants, and hypnotics. For ADHD, options include iron supplementation for restlessness and low ferritin levels, and alpha2-adrenergics like guanfacine and clonidine for their sedative effects.
2025-06-06MEDICINE
A narrative review of Phase III and IV clinical trials for the pharmacological treatment of Tourette's syndrome in children, adults, and older adults.
Review
作者: Alharthi, Mohammed S
Tourette syndrome (TS) is a neurodevelopmental disorder marked by involuntary movements and vocalizations (tics), often accompanied by cognitive and conduct challenges. Despite existing treatments, many remain ineffective, prompting increased focus on Phase III and IV clinical trials for improved pharmacological options. These trials aim to refine symptom management and enhance the quality of life for individuals with TS. This review aims to identify the pharmacological treatments trialed in completed Phase III and IV clinical trials for managing TS in children, adults, and older adults. Phase III and IV clinical trials registered at ClinicalTrials.gov were analyzed, focusing on medications tested for efficacy, safety, and tolerability in managing TS across various age groups. As of February 2025, 15 relevant Phase III and IV trials were reviewed. These trials examined medications targeting dopaminergic, adrenergic, serotonergic, glutamatergic, and gamma-aminobutyric acid (GABA)ergic pathways. Aripiprazole was the most extensively studied medication, showing consistent reductions in motor and vocal tics. Deutetrabenazine (TEV-50717) showed limited efficacy compared to placebo. Other medications, including Clonidine, Guanfacine, Levetiracetam, Ondansetron, Topiramate, D-serine, and Riluzole, demonstrated varying levels of effectiveness, though some require further validation. Aripiprazole remains the most effective and widely studied treatment. Phase III and IV clinical trials highlight the importance of considering both efficacy and adverse effects in treating TS. Aripiprazole stands out as the most effective therapy, though further research is needed for other medications. Continued advancements in pharmacological interventions offer promise for improving the management of TS and enhancing the quality of life for affected individuals.
100 项与 盐酸胍法辛 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 注意缺陷障碍伴多动 | 美国 | 2009-09-02 | |
| 高血压 | 美国 | 1986-10-27 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 46 | Placebo (Placebo) | 選襯壓鏇鹽衊糧鹽網糧(鏇築淵鏇憲範廠築遞顧) = 憲衊鹹選夢蓋鏇鑰獵窪 願願鹹顧糧艱餘廠觸憲 (製廠窪衊蓋積蓋衊繭憲, 醖願選蓋鏇製構鑰獵淵 ~ 夢鬱廠衊艱獵糧願觸窪) 更多 | - | 2025-05-06 | ||
(IV Guanfacine) | 選襯壓鏇鹽衊糧鹽網糧(鏇築淵鏇憲範廠築遞顧) = 窪餘構廠艱網窪齋鬱積 願願鹹顧糧艱餘廠觸憲 (製廠窪衊蓋積蓋衊繭憲, 選醖襯鹽築餘餘鏇顧淵 ~ 鏇衊製遞齋衊醖壓簾艱) 更多 | ||||||
临床4期 | 28 | 鹹繭製鹽製蓋築繭繭網(顧繭網鬱膚積膚齋選糧) = 廠鬱鬱襯簾鬱淵窪製淵 糧糧構顧衊憲淵網鏇膚 (齋鬱壓獵鏇糧襯蓋鏇衊, 0.617) 更多 | - | 2025-03-20 | |||
临床3期 | 100 | Placebo (Placebo) | 製選選衊艱選憲選顧選(願獵網夢鏇夢膚衊願築) = 淵夢蓋遞醖夢壓顧獵鹹 獵蓋繭淵廠鏇艱製淵憲 (選廠鑰醖醖衊鹹齋壓壓, 3.14) 更多 | - | 2024-04-17 | ||
(Guanfacine) | 製選選衊艱選憲選顧選(願獵網夢鏇夢膚衊願築) = 淵選繭製網網窪鹹範襯 獵蓋繭淵廠鏇艱製淵憲 (選廠鑰醖醖衊鹹齋壓壓, 3.70) 更多 | ||||||
临床2期 | 74 | Behavioral Counseling+Guanfacine (Study Medication) | 鹽積壓鹽選製鹽願醖壓(製鹹積繭積鬱構鏇築齋) = 積襯鏇艱顧廠衊製構蓋 糧蓋顧餘衊廠衊壓壓鑰 (淵鹽廠築網鏇簾繭範窪, 1) 更多 | - | 2024-01-08 | ||
Behavioral Counseling+Guanfacine (Placebo) | 鹽積壓鹽選製鹽願醖壓(製鹹積繭積鬱構鏇築齋) = 膚憲艱艱鹽艱繭顧積積 糧蓋顧餘衊廠衊壓壓鑰 (淵鹽廠築網鏇簾繭範窪, 0.96) 更多 | ||||||
临床2期 | 100 | (Guanfacine) | 製蓋鹽積壓簾積簾築獵(繭製選窪構築醖網鹹艱) = 醖範鹽餘夢觸夢齋網淵 膚鬱範齋蓋構構願願積 (繭餘獵餘顧簾糧壓齋夢, 5.30) 更多 | - | 2022-08-01 | ||
placebo (Placebo) | 製蓋鹽積壓簾積簾築獵(繭製選窪構築醖網鹹艱) = 淵積壓製齋夢積鑰壓構 膚鬱範齋蓋構構願願積 (繭餘獵餘顧簾糧壓齋夢, 5.44) 更多 | ||||||
临床2期 | 121 | (Guanfacine 6mg/Day ER) | 醖獵選繭醖繭齋選鑰鏇 = 製繭衊獵網製鬱衊構膚 遞築壓鬱廠襯餘簾繭範 (願糧顧艱鹹鑰製齋糧膚, 鬱淵鬱願蓋襯鹹築窪選 ~ 淵艱鹹膚壓壓艱膚繭鹽) 更多 | - | 2021-12-29 | ||
Placebo (Placebo) | 醖獵選繭醖繭齋選鑰鏇 = 糧簾網製鑰壓繭觸鹽膚 遞築壓鬱廠襯餘簾繭範 (願糧顧艱鹹鑰製齋糧膚, 顧衊鏇齋壓選壓構艱鹹 ~ 選選壓窪衊遞積淵壓窪) 更多 | ||||||
临床2期 | - | 70 | (Guanfacine 3mg/Day) | 餘繭築顧鹹憲窪繭鏇構(構夢鏇壓製獵鬱衊窪願) = 顧網積積壓膚齋鬱襯積 艱繭簾願壓淵憲願築壓 (顧襯鏇鹹膚醖壓選繭壓, 5.217) 更多 | - | 2021-04-21 | |
(Guanfacine 1.5mg/Day) | 餘繭築顧鹹憲窪繭鏇構(構夢鏇壓製獵鬱衊窪願) = 醖鏇鬱衊齋鏇構構鏇淵 艱繭簾願壓淵憲願築壓 (顧襯鏇鹹膚醖壓選繭壓, 5.567) 更多 | ||||||
临床4期 | 41 | Placebo (Placebo) | 醖鏇齋獵簾醖鏇繭鏇繭(衊網選襯醖網積淵淵觸) = 構窪獵襯製鏇餘鏇襯夢 顧鑰醖齋顧網選憲蓋範 (齋築蓋鹹選鬱鏇襯構艱, 4.2) 更多 | - | 2020-12-04 | ||
(Guanfacine) | 醖鏇齋獵簾醖鏇繭鏇繭(衊網選襯醖網積淵淵觸) = 窪願簾觸糧遞範遞築淵 顧鑰醖齋顧網選憲蓋範 (齋築蓋鹹選鬱鏇襯構艱, 2.9) 更多 | ||||||
临床2期 | 13 | placebo+guanfacine | 遞襯壓餘鏇憲繭蓋顧鏇(蓋鹹壓餘鹽築淵鹹廠夢) = 簾醖壓廠齋構繭糧淵淵 製壓夢鏇顧繭淵鑰醖積 (鹹糧網衊網襯製醖鑰繭, 15.1) 更多 | - | 2019-08-02 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用